Clinical Trials Browser

INDUSTRY × Has announcements × enzalutamide × Clear all

NCT02319837 2026-05-07

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Phase 3 Active not recruiting

1,068 enrolled 20 charts 1 FDA

Prostatic Neoplasms

NCT03395197 2026-04-22

TALAPRO-2

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

NCT02003924 2026-01-27

PROSPER

Phase 3 Completed

1,401 enrolled 25 charts 1 FDA

Prostatic Neoplasms

NCT02677896 2025-10-24

ARCHES

Phase 3 Completed

1,150 enrolled 23 charts 1 FDA

Metastatic Hormone Sensitive Prostate Cancer

NCT02975934 2025-07-25

TRITON3

Phase 3 Completed

405 enrolled 34 charts 1 FDA

Metastatic Castration Resistant Prostate Cancer

NCT02987543 2023-10-06

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Phase 3 Completed

387 enrolled 16 charts 1 FDA

Metastatic Castration-resistant Prostate Cancer